Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(3):168-169; doi:10.1093/jnci/93.3.168
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 3, 168-169, February 7, 2001
© 2001 Oxford University Press

NEWS

Taxane Evidence Inconclusive in Adjuvant Setting

Judith Randal

The taxane drug paclitaxel (Taxol) prolongs the lives of many women whose breast cancers have metastasized. So it seems hardly far-fetched that it might also be good as adjuvant—i.e., postsurgical—therapy for women with early stage breast cancers. Indeed, the U.S. Food and Drug Administration approved Taxol for this purpose in 1999. (The agency has also approved Taxotere, a close chemical cousin of Taxol, but only for advanced disease.)

All of which is why early breast cancer patient Anna G. (at her request not her real name) decided to go to the Consensus Conference on Adjuvant Therapy for Breast Cancer at the National Institutes of Health in Bethesda, Md., in November. The 36-year-old teacher was nearing the end of 3 months of initial adjuvant chemotherapy with doxorubicin and cyclophosphamide and was planning on 3 months of Taxol . . . [Full Text of this Article]

"Clearly Worthwhile"

Conflicting Data

Study Ongoing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?